Does newest immunomodulative treatment in patients with psoriasis impact growth and transformation of melanocytic nevi in patients with psoriasis? Preliminary results from a prospective cohort study.

INTRODUCTION

Patients with psoriasis treated with biologic therapy are considered to have increased risk of developing skin neoplasms. The impact of novel therapies on the development and biology of melanocytic lesions is not completely known. The aim of the study was assess if the treatment with biologics exerts effects on the melanocytic nevi.

MATERIAL AND

METHODS

Dermoscopy and videodermoscopic imaging of 276 melanocytic lesions were performed at the initial visit and after one year in 13 patients with psoriasis treated with IL-12/23 inhibitors, IL-23 inhibitors or IL-17 inhibitors.

RESULTS

The nevi size significantly increased at the one-year follow-up in the whole study group and in patients treated either with IL-23 inhibitors or IL-12/23 inhibitor. 2% of melanocytic nevi showed an increase in any of the scores (ABCD score, 7-Point Checklist score, CASH score) or at least 1-mm change in the diameter at the one-year follow-up; however, these changes were not statistically significant between the different therapy groups.

CONCLUSIONS

Although treatment with novel groups of biologics leads to an increase in nevi size, it does not contribute to significant structural or color changes in melanocytic nevi or to the development of dysplastic nevi or melanoma at the one-year follow-up.